ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Randomized Trial"

  • Abstract Number: L08 • ACR Convergence 2024

    A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee

    Limin Ren1, Wenjie Zheng2, Zhenpeng Guan3, Yang Zhang4, Zeyu Huang5, Tong Li6, Yuwei Peng7, Qiuli Wu8, Wei Gou9, Wei Zhao10, Pengyan Qiao11, Xiaoli Pan12 and Guang-Liang Jiang13, 1Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, 2Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, 3Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, 4Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, 5West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, 6Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, 7PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, 8Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, 9Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, 10Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, 11Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, 12Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, 13Xgene Pharmaceutical, Lexington, MA

    Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
  • Abstract Number: L14 • ACR Convergence 2024

    A Withdrawal Study of Colchicine in Behçet Syndrome

    Basak Sirin1, Sinem Nihal Esatoglu2, Hasan Yazıcı3 and Gulen Hatemi4, 1Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul, Turkey, 3Academic Hospital, Istanbul, Turkey, 4Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul,Türkiye, Istanbul, Turkey

    Background/Purpose: Previous randomized controlled studies reported conflicting results regarding the effectiveness of colchicine on oral ulcers in Behçet syndrome (BS). A randomized drug discontinuation design…
  • Abstract Number: L15 • ACR Convergence 2024

    LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial

    Philip Conaghan1, Ali Guermazi2, Nathaniel Katz3, Asger Bihlet4, Dror Rom5, Michael Perkins6, Bernadette Hughes6, Claire Herholdt6, Iwona Bombelka6 and Simon Westbrook6, 1University of Leeds, Leeds, United Kingdom, 2Boston University, West Roxbury, MA, 3Rin Sof Innovation, Ltd, Boston, MA, 4NBCD A/S, Soeborg, Denmark, 5Prosoft Clinical, Chesterbrook, 6Levicept Ltd, Ramsgate, United Kingdom

    Background/Purpose: There is an urgent need for new therapies to treat OA. Excess neurotrophins (NT) are implicated in OA and other painful conditions. Previous OA…
  • Abstract Number: L16 • ACR Convergence 2024

    Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial

    Megan Clowse1, David Isenberg2, Joan Merrill3, Thomas Dörner4, Michelle Petri5, Edward Vital6, Eric Morand7, Teri Jimenez8, Stephen Brookes9, Janine Gaiha-Rohrbach10, Christophe Martin11, Annette Nelde12 and Christian Stach13, 1Division of Rheumatology and Immunology, Duke University, Durham, NC, 2Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 5Johns Hopkins University School of Medicine, Baltimore, MD, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 8UCB, Raleigh, NC, 9Biogen, Maidenhead, United Kingdom, 10Biogen, Cambridge, MA, 11UCB, Slough, United Kingdom, 12Biogen, Baar, Switzerland, 13UCB, Monheim am Rhein, Germany

    Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
  • Abstract Number: 0217 • ACR Convergence 2024

    Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds

    Joy Buie1, Safoah Agyemang1 and Joan Merrill2, 1Lupus Foundation of America, Washington, DC, 2Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: With many emerging treatments in development for lupus, clinical trial recruitment has become increasingly difficult. Growing appreciation of patient input into trial design may be of …
  • Abstract Number: 1131 • ACR Convergence 2024

    Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis

    Vivian Laquer1, Leon Kircik2, Neil Sadick3, Jamie Weisman4, Yiwei Zhao5, Jessamyn Blau5, Wenwen Zhang6, Jonathan Uy5, Warren Winkelman6 and Melinda Gooderham7, 1First OC Dermatology Research, Fountain Valley, CA, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3Weill Cornell Medical College, New York, NY, 4Piedmont Atlanta, Atlanta, GA, 5Takeda Development Center Americas, Inc., Cambridge, MA, 6Takeda Development Center Americas, Inc., Cambridge, 7SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada

    Background/Purpose: Zasocitinib (TAK-279) is a highly selective, allosteric, oral inhibitor of tyrosine kinase 2 (TYK2). TYK2 mediates signaling from cytokines involved in the pathogenesis of…
  • Abstract Number: 1542 • ACR Convergence 2024

    Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus

    Arezou Khosroshahi1, Sarah Welsh2, Liangwei Wang2, David Larson2 and Nisha Jain2, 1Emory University, Atlanta, GA, 2Amgen, Inc., Rockville, MD

    Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…
  • Abstract Number: 1735 • ACR Convergence 2024

    High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial

    Kristofer Andreasson1, Cecilia Leijding1, Maryam Dastmalchi2, Antonella Notarnicola3, Stefano Gastaldello1, Heléne Sandlund2, Daniel Andersson4, Ingrid Lundberg5 and Helene Alexanderson2, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska University hospital, Stockholm, Sweden, 3Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 4Karolinska Institutet, Solna, Sweden, 5Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Exercise is a recognized adjunctive therapy for patients with idiopathic inflammatory myopathies (IIM), enhancing physical capacity and reducing inflammation. Hitherto, moderate-to-intensive exercise has been…
  • Abstract Number: 2353 • ACR Convergence 2024

    Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies

    Philip Mease1, Alice Gottlieb2, Iain McInnes3, Natalie J. Shiff4, Toby Thomas5, Emmanouil Rampakakis6, Francois Nantel7, Frederic Lavie8 and Proton Rahman9, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, 3University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 4Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, 5Janssen Pharmaceuticals, Horsham, PA, 6McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 7Nantel MedSci Consult, Montreal, QC, Canada, 8Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 9Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada

    Background/Purpose: In the Phase 3 DISCOVER (D)-1 and -2 studies, guselkumab (GUS; IL-23p19-subunit inhibitor) 100 mg every 4 weeks (Q4W) or Q8W significantly improved joint…
  • Abstract Number: 2686 • ACR Convergence 2024

    Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells

    David Fox1, Laura Cooney2, Lia Stelzig3, Robert Lafyatis4, Johann Gudjonsson5, Lam Tsoi6, Maureen Mayes7, Ankoor Shah8, Suzanne Kafaja9, William Barry3, Ellen Goldmuntz10, Dawn Smilek11 and Dinesh Khanna6, 1University of Michigan, Dexter, MI, 2University of Michigan and Immune Tolerance Network, Ann Arbor, MI, 3Rho, Durham, NC, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 5Department of Dermatology, University of Michigan, Ann Arbor, MI, 6University of Michigan, Ann Arbor, MI, 7UTHealth Houston Division of Rheumatology, Houston, TX, 8Duke University, Durham, NC, 9Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 10Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, 11Immune Tolerance Network, UCSF, San Francisco, CA

    Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…
  • Abstract Number: 0290 • ACR Convergence 2024

    Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program

    Mark Lebwohl1, Richard Warren2, Shinichi Imafuku3, Jerry Bagel4, April W. Armstrong5, Thierry Passeron6, Subhashis Banerjee7, Renata M. Kisa8, Matthew J. Colombo7, Thomas Scharnitz8, Kim Hoyt8, Diamant Thaçi9 and Andrew Blauvelt10, 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 2Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, 4Psoriasis Treatment Center of New Jersey, East Windsor, 5University of California Los Angeles, Los Angeles, 6Université Côte d’Azur, University Hospital of Nice, Nice, France, 7Bristol Myers Squibb, Princeton, NJ, 8Bristol Myers Squibb, Princeton, 9Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, 10Oregon Medical Research Center, Portland, OR

    Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
  • Abstract Number: 1137 • ACR Convergence 2024

    Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)

    Kristina Callis Duffin1, Christopher E. M. Griffiths2, Matthias Hoffmann3, Andrew Blauvelt4, Eugene Balagula5, Andrew Napoli5, Ying-Ming Jou5, Rachel Dyme5, Virginia Hala5, andreas pinter6 and Mark Lebwohl7, 1University of Utah, Salt Lake City, 2Dermatology Centre, University of Manchester, Manchester, and King’s College Hospital and King’s College London, London, United Kingdom, 3Private Practice, Witten, Germany, 4Oregon Medical Research Center, Portland, OR, 5Bristol Myers Squibb, Princeton, 6University Hospital of the Goethe University, Frankfurt am Main, Frankfurt, Germany, 7Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the US, EU, and other countries for treatment of adults with…
  • Abstract Number: 1552 • ACR Convergence 2024

    Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial

    Ronald Van Vollenhoven1, Joseph Merola2, Kathryn H. Dao3, Piotr Leszczynski4, Marilyn Pike5, Samantha Pomponi6, Coburn Hobar6, Matthew J. Colombo6, Ravi Koti6, Subhashis Banerjee6, Thomas Wegman7 and Eric Morand8, 1Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 2UT Southwestern Medical Center, Newton, MA, 3Department of Internal Medicine, Division of Rheumatology, The University of Texas Southwestern Medical Center, Dallas, 4Department of Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland, 5Rheumatology, MedPharm Consulting, Inc., Raleigh, NC, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Beaver Falls, PA, 8School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate to severe plaque…
  • Abstract Number: 1988 • ACR Convergence 2024

    A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

    Marta Cossu1, Carolina Bobadilla Mendez2, Amanda Jackson3, Eugene Myshkin4, Grace Liu5, Edwin Lam6, Ulf H. Beier2, Kathleen Weisel2, Brittney Scott2, Jocelyn H. Leu6, Sheng Gao2 and Dessislava Dimitrova2, 1Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, 2Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, 3Janssen Research & Development, LLC, La Jolla, CA, 4Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, 5Janssen Research & Development, LLC, a Johnson & Johnson company, Raritan, NJ, 6Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA

    Background/Purpose: Nipocalimab is a human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn) that selectively reduces IgG levels without impacting antigen presentation, T- and…
  • Abstract Number: 2355 • ACR Convergence 2024

    Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials

    Laure Gossec1, Andra Balanescu2, Maria Antonietta D'Agostino3, Alexis Ogdie4, Philipp Sewerin5, Yu Deng6, Linyu Shi6, Yoshiyuki Sugimoto7, Sheng Zhong6, Yunzhao Xing6, Ralph Lippe6 and Mitsumasa Kishimoto8, 1Sorbonne Université, Paris, France, 2UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, 3Versailles-Saint-Quentin University (INSERM U1173, Laboratoire d’Excellence INFLAMEX); University Hospital Ambroise Paré, Versailles, France, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Bochum, Germany, 6AbbVie Inc., North Chicago, IL, 7AbbVie GK, Tokyo, Tokyo, Japan, 8Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

    Background/Purpose: Risankizumab (RZB), an IL-23 p19 inhibitor, is well tolerated and provides long-term efficacy through 100 weeks in adults with PsA, demonstrated by the phase…
  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology